Pharvaris N.V. - Ordinary Shares — Cash Flow (NASDAQ:PHVS) | MetaTrader

Open full chart

Financials

Overview Statement Statistics Documents

Cash from operating activities —————— — Cash from investing activities —————— — Cash from financing activities —————— — Free cash flow —————— —

News

Reported Earlier, Pharvaris Says Lancet-Published Phase 3 Data Show Deucrictibant IR Delivered Symptom Relief In 1.28 Hours And Complete Resolution In 11.95 Hours For HAE Attacks, With NDA And MAA Under Review

Pharvaris N.V. (PHVS) Presents at Morgan Stanley 24th Annual Global Healthcare Conference Transcript

PHVS Stock Rises 10% in a Month: What Is Driving the Rally?

Pharvaris N.V. (PHVS) Discusses Topline Results of Chapter-3 Phase III Study on Deucrictibant for Prophylactic Treatment of Hereditary Angioedema - Slideshow (NASDAQ:PHVS) 2026-09-10

Stocks Settle Lower on Middle East Jitters

Pharvaris N.V. (PHVS) Discusses Topline Results of Chapter-3 Phase III Study on Deucrictibant for Prophylactic Treatment of Hereditary Angioedema Transcript

Why These Two Hot Biotech Stocks Just Surged To Record Highs

Why Is Pharvaris Stock Soaring Tuesday? - Pharvaris (NASDAQ:PHVS)

Wall Street Analysts Think Pharvaris (PHVS) Could Surge 43.03%: Read This Before Placing a Bet

Wall Street Analysts Think Pharvaris (PHVS) Could Surge 43.03%: Read This Before Placing a Bet

Here's Why Pharvaris N.V. (PHVS) is a Great Momentum Stock to Buy

Wall Street Analysts Believe Pharvaris (PHVS) Could Rally 36.16%: Here's is How to Trade